SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is seeing significant bullish momentum after a short-seller retracted serious allegations against a major shareholder, driving a rebound and sparking community discussion around an imminent short squeeze and anticipated strong earnings.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio Inc. is trending after the FDA issued a Complete Response Letter (CRL) for its RGX-121 gene therapy, citing trial design concerns and intensifying community discussion around the stringent regulatory environment for gene therapies. While many anticipate further stock depreciation and question the company's outlook, some investors highlight other pipeline assets as potential future drivers.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group (CRDO) is experiencing a significant surge following its pre-announcement of substantially increased revenue guidance for the current quarter and strong fiscal year growth projections. This positive outlook is fueling investor excitement, with many anticipating further upside as the company, a key player in AI data center connectivity, continues to benefit from accelerating hyperscaler capital expenditures amidst ongoing discussions about its technological positioning.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON Semiconductor is trending due to its latest earnings, where a revenue miss and softer forward guidance, particularly against a backdrop of ongoing automotive market softness, have disappointed investors. Community discussion centers on the company's valuation, perceived lack of growth beyond pure AI chip plays, and the broader impact of the EV sector slowdown.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings Inc. is trending after its stock plunged following the abrupt exits of its CFO and general counsel amidst an accounting review and delayed SEC filings, leading to a split in the community between those fearing significant financial issues and others who believe the drastic sell-off presents an overdone buying opportunity.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is seeing significant discussion as investors grapple with its recent price action ahead of its upcoming Q4 earnings report. Community sentiment is split between those who view its AI-powered lending model as massively undervalued given its profitability and prudent risk management, and others concerned by its conservative growth outlook and the broader fintech sector's current struggles.

Upwork, Inc. is an online marketplace which engages in the provision of businesses to find, hire, and pay freelancers for short-term and longer-term projects. Its marketplace offerings include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The company was founded by Odysseas Tsatalos and Efstratios Karamanlakis in December 2013 and is headquartered in Palo Alto, CA.

Upwork Inc

Upwork is actively discussed after its latest earnings surpassed expectations with record revenue and profitability, propelled by its AI initiatives including Uma. While many anticipate a short squeeze and highlight undervaluation in the evolving gig economy, others voice frustration over the stock's muted response and concerns about client growth in an AI-driven landscape.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

Monday.com is experiencing a significant sell-off after providing weaker-than-expected revenue guidance for the upcoming quarter and fiscal year, despite reporting stronger-than-anticipated earnings and revenue growth. The community is actively debating whether this dip is an overreaction, weighing the company's strong customer retention and large cash reserves against intensifying market fears that AI tools could disrupt the traditional software business model.

Amentum Holdings, Inc. engages in mission-critical, technology-driven services in government and commercial markets. It operates through the Digital Solutions and Global Engineering Solutions segments. The Digital Solutions segment provides advanced digital and data-driven solutions including intelligence analytics, space system development, cybersecurity, and next generation IT. The Global Engineering Solutions segment manages large-scale environmental remediation, nuclear power solutions, platform engineering, sustainment and supply chain management. The company was founded on November 26, 2019 and is headquartered in Chantilly, VA.

Amentum Holdings Inc.

Amentum Holdings is trending after recent earnings revealed strong EPS growth despite a revenue decline, driven by an expanding backlog and numerous new contracts in critical nuclear, defense, and space sectors. While some in the community express frustration over the stock's price action, many view these long-term contract wins and the company's perceived undervaluation as catalysts for substantial future growth.

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases. Its mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function, enabling patients with these disorders to live fuller and healthier lives. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium.

AgomAb Therapeutics NV - ADR

AGMB is experiencing heightened attention as a new IPO amid extreme volatility, with community discussions largely focused on its low float potentially fueling a short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FY2025 EPS Estimates for Pharming Group Increased by Analyst

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) - Investment analysts at HC Wainwright increased their FY2025 earnings estimates for shares of Pharming Group in a note issued to...

Pharming Group Q4 EPS Forecast Increased by HC Wainwright

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) - Equities research analysts at HC Wainwright increased their Q4 2025 earnings per share estimates for shares of Pharming Group in a note...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming...

<ul class="summary-bullets"><li>FDA feedback focused on dosing and testing questions, not safety or effectiveness concerns.</li><li>Joenja’s existing approval and sales in patients aged 12 and older remain unchanged.</li><li>Pharming said it plans to work with regulators and pursue a resubmission path.</li></ul>Pharming Group shares drew heightened retail chatter on Monday after the company said it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its application to expand the use of Joenja in younger pediatric patients, while signaling confidence it can address the agency’s concerns.<h2 class="st-heading-2">FDA Requests Additional Pediatric Data</h2>Dutch drug developer Pharming announced that it had received a Complete Response Letter from the FDA on its filing for the approval of Joenja in children aged 4-11 with activated phosphoinositide 3-kinase delta syndrome (APDS).APDS is a rare primary immunodeficiency disorder in which the immune system does not function properly, resulting in recurrent infections and other complications associated with immune dysfunction. Pharming’s Joenja is an oral medication indicated to treat APDS.The company said the FDA was concerned that younger children may not be receiving sufficient doses at the proposed levels and requested additional data to confirm appropriate dosing in younger patients. The agency also flagged a technical issue with a manufacturing test and requested additional information.Pharming expressed confidence that it can resolve both inquiries. The company added that it plans to meet with the FDA to discuss next steps for resubmission, including a Type A meeting.<h2 class="st-heading-2">Approval For Older Patients Unaffected</h2>The company emphasized that the Complete Response Letter does not impact Joenja’s existing FDA approval for adult and pediatric patients aged 12 years and older, which has been in place since March 2023.CEO Fabrice Chouraqui said Pharming remains focused on making Joenja available to younger children with APDS, noting that there are currently no approved targeted treatments globally for patients under the age of 12.<h2 class="st-heading-2">Trial Results Backing The Application</h2>The application was backed by data from a late-stage clinical study in children aged 4 to 11. Pharming said that over 12 weeks of treatment, children showed reduced lymph node swelling and healthier immune cell levels, signs that the drug was helping correct the immune problem caused by APDS.Safety data from up to eight months of treatment were also included in the submission. The company said all treatment-emergent adverse events were mild to moderate, no drug-related serious adverse events were reported, and all patients completed the 12-week treatment period.In October 2025, the FDA granted the application Priority Review, citing the potential for significant improvements in the treatment of a serious condition.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Pharming was ‘bullish’ amid ‘high’ message volume ahead of the company’s Virtual Investor Day on Tuesday.One user called the FDA response a “soft” CRL, noting that it focused on dosing and testing issues rather than safety, and that Joenja remains approved and generating revenue for patients aged 12 and older.<stembedurl>https://stocktwits.com/BioSpecialOne/message/643641905</stembedurl>Another user said, “will buy the dip. Hopefully it’s a large drop”<stembedurl>https://stocktwits.com/CrispDry/message/643612689</stembedurl><a href="https://stocktwits.com/symbol/PHAR">U.S.-listed shares of Pharming</a> have surged over 130% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Pharming logo is displayed on the screen of the tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Pharming Stock Draws Retail Buzz After FDA Seeks More Data For Pediatric Immune Drug — Why Investors Aren’t Panicking

The company expressed confidence that it can resolve the FDA’s inquiries. 

Equity

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Update

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) was the recipient of a significant decrease in short interest in the month of December. As of December 31st, there was short interest...

Pharming Group (OTCMKTS:PHGUF) Sets New 1-Year High - Here's What Happened

Pharming Group (OTCMKTS:PHGUF) Hits New 12-Month High - Time to Buy...

Pharming Group (NASDAQ:PHAR) Lowered to "Hold" Rating by Zacks Research

Zacks Research lowered shares of Pharming Group from a "strong-buy" rating to a "hold" rating in a research note on Thursday...

Pharming Group (NASDAQ:PHAR) Shares Gap Down - Here's What Happened

Pharming Group (NASDAQ:PHAR) Shares Gap Down - Time to Sell...

Pharming Group (NASDAQ:PHAR) Shares Up 4.4% - Should You Buy?

Pharming Group (NASDAQ:PHAR) Trading 4.4% Higher - Here's What Happened...

Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume - Should You Buy?

Pharming Group (NASDAQ:PHAR) Sees Large Volume Increase - Here's Why...

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following segments: RUCONEST®, Joenja®, Europe, and Rest of the World. The company was founded on November 11, 1988, and is headquartered in Leiden, the Netherlands.

Pharming Group N.V. - ADR

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

PHAR
Pharming Group

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest PHAR News

PHARPharming Group